Measles, Mumps, and Rubella - Centers for Disease Control and ...

More documents

Recommendations

Info

40 MMWR May 22, 1998measles who has no identified source of infection and no epidemiologic linkage toanother confirmed case. The Measles Virus Laboratory of CDC’s National Center forInfectious Diseases has provided training to all state public health laboratories to performsuch testing.Serologic diagnosis of measles can also be confirmed by a significant rise in antibodytiter between acute- and convalescent-phase serum specimens. Typically, theacute-phase serum specimen is obtained within 1–3 days after rash onset and the convalescent-phasespecimen is obtained approximately 2–4 weeks later. This methodhas been largely supplanted by IgM assays which can be done on a single serumspecimen obtained soon after rash onset.Asymptomatic measles reinfection can occur among persons who have previouslydeveloped antibodies from vaccination or from natural disease. Symptomatic reinfectionsaccompanied by rises in measles antibody titers are rare, and those resulting indetectable measles IgM antibody occur even more rarely.Molecular characterization of measles virus isolates has become an important toolfor defining the epidemiologic features of measles during periods of low disease incidenceand for documenting the impact of measles elimination efforts (16 ). In additionto serologic confirmation, a specimen (e.g., urine or nasopharyngeal mucus) for measlesvirus isolation and genetic characterization should be collected as close to thetime of rash onset as possible. Delay in collection of these clinical specimens reducesthe chance of isolating measles virus. Clinicians who have a patient with suspectedmeasles should immediately contact their local or state health departments concerningadditional information about collecting and shipping urine and nasal specimensfor measles virus isolation. Molecular characterization of the measles virus isolatedfrom urine or nasopharyngeal specimens requires considerable time and cannot beused for diagnosis of measles. Use of oral fluid in tests for detecting measles IgM andIgG antibodies is being investigated (225 ).Measles Outbreak ControlThe local or state health department should be contacted immediately when suspectedcases of measles occur in a community. All reports of suspected measles casesshould be investigated promptly. Because of the potential for rapid spread of the disease,one confirmed case of measles in a community is an urgent public healthsituation. Once a case is confirmed, prompt vaccination of susceptible persons at riskfor exposure may help prevent dissemination of measles. Control activities should notbe delayed pending the return of laboratory results from persons with suspected orprobable cases. Persons who cannot readily provide acceptable evidence of measlesimmunity (Table 1) should be vaccinated or excluded from the setting of the outbreak(e.g., school, day care facility, hospital, clinic). Almost all persons who are excludedfrom an outbreak area because they lack acceptable evidence of immunity quicklycomply with vaccination requirements. Persons exempted from measles vaccinationfor medical, religious, or other reasons should be excluded from involved institutionsin the outbreak area until 21 days after the onset of rash in the last case of measles.Mass revaccination of entire communities generally is not necessary. Staff of theNational Immunization Program, CDC, are available to assist health departments indeveloping an outbreak control strategy.
Vol. 47 / No. RR-8 MMWR 41Measles Outbreaks Among Preschool-Aged ChildrenAlthough most infants are protected from measles by maternal antibody, the diseaseis often more severe when it affects children aged
Page 1 and 2: May 22, 1998 / Vol. 47 / No. RR-8TM
Page 3 and 4: Vol. 47 / No. RR-8 MMWR iContentsIn
Page 5 and 6: Vol. 47 / No. RR-8 MMWR iiiAdvisory
Page 7 and 8: Vol. 47 / No. RR-8 MMWR vAdvisory C
Page 9 and 10: Vol. 47 / No. RR-8 MMWR 1Measles, M
Page 11 and 12: Vol. 47 / No. RR-8 MMWR 3greatest d
Page 13 and 14: Vol. 47 / No. RR-8 MMWR 5Rubella El
Page 15 and 16: Vol. 47 / No. RR-8 MMWR 7intermedia
Page 17 and 18: Vol. 47 / No. RR-8 MMWR 9Vaccine Sh
Page 19 and 20: TABLE 1. Acceptable presumptive evi
Page 21 and 22: Vol. 47 / No. RR-8 MMWR 13When meas
Page 23 and 24: Vol. 47 / No. RR-8 MMWR 15evidence
Page 25 and 26: Vol. 47 / No. RR-8 MMWR 17Women of
Page 27 and 28: Vol. 47 / No. RR-8 MMWR 194% among
Page 29 and 30: Vol. 47 / No. RR-8 MMWR 21SPECIAL C
Page 31 and 32: Vol. 47 / No. RR-8 MMWR 23protectio
Page 33 and 34: Vol. 47 / No. RR-8 MMWR 25Passively
Page 35 and 36: Vol. 47 / No. RR-8 MMWR 27are liste
Page 37 and 38: Vol. 47 / No. RR-8 MMWR 29In 1994,
Page 39 and 40: Vol. 47 / No. RR-8 MMWR 31women, th
Page 41 and 42: Vol. 47 / No. RR-8 MMWR 33observed
Page 43 and 44: Vol. 47 / No. RR-8 MMWR 35a contact
Page 45 and 46: Vol. 47 / No. RR-8 MMWR 37SteroidsS
Page 47: Vol. 47 / No. RR-8 MMWR 39• is no
Page 51 and 52: Vol. 47 / No. RR-8 MMWR 43Cases mee
Page 53 and 54: Vol. 47 / No. RR-8 MMWR 45rubella-s
Page 55 and 56: Vol. 47 / No. RR-8 MMWR 47Laborator
Page 57 and 58: Vol. 47 / No. RR-8 MMWR 4927. Lee S
Page 59 and 60: Vol. 47 / No. RR-8 MMWR 5181. Briss
Page 61 and 62: Vol. 47 / No. RR-8 MMWR 53130. CDC.
Page 63 and 64: Vol. 47 / No. RR-8 MMWR 55179. Amer
Page 65 and 66: Vol. 47 / No. RR-8 MMWR 57230. Amer
Page 67: MMWRThe Morbidity and Mortality Wee

Measles, Mumps, and Rubella - Centers for Disease Control and ...

Create successful ePaper yourself

Delete template?

Save as template?